Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Angela R Branche; Nadine G Rouphael; Cecilia Losada; Lindsey R Baden; Evan J Anderson; Anne F Luetkemeyer; David J Diemert; Patricia L Winokur; Rachel M Presti; Angelica C Kottkamp; Ann R Falsey; Sharon E Frey; Richard Rupp; Martín Bäcker; Richard M Novak; Emmanuel B Walter; Lisa A Jackson; Susan J Little; Lilly C Immergluck; Siham M Mahgoub; Jennifer A Whitaker; Tara M Babu; Paul A Goepfert; Dahlene N Fusco; Robert L Atmar; Christine M Posavad; Antonia Netzl; Derek J Smith; Kalyani Telu; Jinjian Mu; Mat Makowski; Mamodikoe K Makhene; Crandon Sonja; David C Montefiori; Paul C Roberts; John H Beigel

doi:10.1101/2023.01.31.23285306

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

medRxiv [Preprint]. 2023 Mar 31:2023.01.31.23285306. doi: 10.1101/2023.01.31.23285306.

Authors

Angela R Branche¹, Nadine G Rouphael², Cecilia Losada², Lindsey R Baden³, Evan J Anderson⁴, Anne F Luetkemeyer⁵, David J Diemert⁶, Patricia L Winokur⁷, Rachel M Presti⁸, Angelica C Kottkamp⁹, Ann R Falsey¹, Sharon E Frey¹⁰, Richard Rupp¹¹, Martín Bäcker¹², Richard M Novak¹³, Emmanuel B Walter¹⁴, Lisa A Jackson¹⁵, Susan J Little¹⁶, Lilly C Immergluck¹⁷, Siham M Mahgoub¹⁸, Jennifer A Whitaker¹⁹, Tara M Babu²⁰, Paul A Goepfert²¹, Dahlene N Fusco²², Robert L Atmar¹⁹, Christine M Posavad²³, Antonia Netzl²⁴, Derek J Smith²⁴, Kalyani Telu²⁵, Jinjian Mu²⁵, Mat Makowski²⁵, Mamodikoe K Makhene²⁶, Crandon Sonja²⁶, David C Montefiori²⁷, Paul C Roberts²⁶, John H Beigel²⁶

Affiliations

¹ University of Rochester VTEU, Rochester, NY.
² Emory University Hope Clinic, Decatur, GA.
³ Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁴ Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA.
⁵ Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA.
⁶ George Washington Vaccine Research Unit, George Washington University, Washington D.C.
⁷ University of Iowa College of Medicine, Iowa City, IA.
⁸ Washington University School of Medicine, St. Louis, MO.
⁹ NYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY.
¹⁰ Saint Louis University, Center for Vaccine Development, St. Louis, MO.
¹¹ University of Texas Medical Branch, Galveston, TX.
¹² NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY.
¹³ University of Illinois at Chicago-Project WISH, Chicago, IL.
¹⁴ Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC.
¹⁵ Kaiser Permanente Washington Health Research Institute, Seattle, WA.
¹⁶ Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA.
¹⁷ Morehouse School of Medicine, Atlanta, GA.
¹⁸ Howard University College of Medicine, Howard University Hospital, Washington D.C.
¹⁹ Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX.
²⁰ Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA.
²¹ University of Alabama at Birmingham, Birmingham, AL.
²² Tulane University School of Medicine, New Orleans, LA.
²³ IDCRC Laboratory Operations Unit - Fred Hutchinson Cancer Center and University of Washington, Seattle, WA.
²⁴ Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.
²⁵ The Emmes Company, LLC, Rockville, MD.
²⁶ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
²⁷ Duke University, Durham, NC.

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Publication types

Preprint

Abstract

Publication types

Grants and funding